visitant ::
identificació
|
|||||||||||||||
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español |
Pàgina inicial > Articles > Articles publicats > Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors |
Data: | 2019 |
Resum: | Trisomy 21 (T21) causes Down syndrome (DS), affecting immune and neurological function by ill-defined mechanisms. Here we report a large metabolomics study of plasma and cerebrospinal fluid, showing in independent cohorts that people with DS produce elevated levels of kynurenine and quinolinic acid, two tryptophan catabolites with potent immunosuppressive and neurotoxic properties, respectively. Immune cells of people with DS overexpress IDO1, the rate-limiting enzyme in the kynurenine pathway (KP) and a known interferon (IFN)-stimulated gene. Furthermore, the levels of IFN-inducible cytokines positively correlate with KP dysregulation. Using metabolic tracing assays, we show that overexpression of IFN receptors encoded on chromosome 21 contribute to enhanced IFN stimulation, thereby causing IDO1 overexpression and kynurenine overproduction in cells with T21. Finally, a mouse model of DS carrying triplication of IFN receptors exhibits KP dysregulation. Together, our results reveal a mechanism by which T21 could drive immunosuppression and neurotoxicity in DS. |
Ajuts: | Instituto de Salud Carlos III PI17-01896 Instituto de Salud Carlos III PI14-1561 Instituto de Salud Carlos III PI18-00335 Instituto de Salud Carlos III PI14-01126 Instituto de Salud Carlos III PI16-01825 Instituto de Salud Carlos III PI13-01532 Instituto de Salud Carlos III PI17-01019 |
Nota: | Altres ajuts: This work has also been supported by a "Marató TV3" grant (20141210 to J.F. and 044412 to R.B.). |
Nota: | Altres ajuts: PERIS/SLT006-17-00119 |
Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Llengua: | Anglès |
Document: | Article ; recerca ; Versió publicada |
Matèria: | Chromosome abnormality ; Immunological disorders ; Animals ; Biosynthetic Pathways ; Cell Line ; Chromosomes, Human, Pair 21 ; Cytokines ; Down Syndrome ; Gene Expression ; Humans ; Indoleamine-Pyrrole 2,3,-Dioxygenase ; Kynurenine ; Metabolomics ; Mice, Inbred C57BL ; Quinolinic Acid ; Receptors, Interferon ; Trisomy |
Publicat a: | Nature communications, Vol. 10 Núm. 1 (january 2019) , p. 4766, ISSN 2041-1723 |
11 p, 871.5 KB |